Category: Law
The Center’s Flagship Investment Program provides working capital to early-stage companies
For Immediate Release: Date: February 24, 2010
Contact: Angus G. McQuilken, MLSC VP for Communications
Phone: (617) 921-7749 Email: amcquilken@masslifesciences.com
Waltham, MA – The Board of Directors of the Massachusetts Life Sciences Center today approved the launch of the 2010 Accelerator Loan Program, the second year of the Center’s flagship investment program that provides working capital to early-stage life sciences companies. The Center will begin accepting online applications on Wednesday, February 24th, 2010 with an application deadline of Wednesday, March 24, 2010. A subsequent round will be conducted in the fall, with application dates to be announced. Applications will be accepted via the Center’s web site at www.masslifescience.com.
The Program has been capitalized with $5.5 million for 2010. This year’s program will offer loans of up to $750,000 per company, an increase from the 2009 maximum loan amount of $500,000. The Program seeks to “de-risk” start-up companies that are in need of financing to serve as flexible working capital or for the purchase of capital assets to help selected companies achieve product development milestones and obtain private investment. In addition, the loan terms will now include a warrant which will give the Center the right to purchase equity in the company at a specific price within a certain time frame.
 |
|
...But what do I know?
Lessons learned from living through a couple of spin-out companies
|
|
qed@qb3 UCSF
Thursday, March 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)
Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455
http://qb3.org/services/qed-qb3/?searchterm=qed
|
|
Building, Compensating & Motivating
a Leadership Team
|
|
qed@qb3 - UCSF
Thursday, February 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
One of the most critical factors for a company's success is building an excellent team, but finding, recruiting, compensating, and ultimately motivating the best people is extremely challenging. Chris McKinley and Michael Ballenger bring decades of HR and executive recruitment experience to this subject and will share their insights and advice in this seminar.
Christine McKinley has 30 years experience working in entrepreneurial, high growth biotech and medical companies. Prior to founding Round One Resources, she was Sr.VP of Human Resources at Cell Genesys, responsible for strategic and operational HR initiatives, involving extensive staffing of a manufacturing facility, expansion of process development, manufacturing and clinical operations, merger, acquisition and restructuring activities. She began as one of the earlier employees of Genentech.
Michael Ballenger specializes in Board of Director, CEO searches as well as officer-level assignments in research, product development and all business functions. He has 23 years of experience in executive search in all segments of the life science/healthcare product industry and has focused his last 10 years on work with start-up and development stage companies. He was previously the Managing Partner of Highland Partner's San Francisco office where he built the company's first Life Science/Healthcare Products Practice and was also Sr. Director of Human Resources for Genentech.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=197756
Bread Board's NextFab Studio opened January 22, allowing students, adults, researchers and companies to fabricate and prototype novel designs in 3D. NextFab and Bread Board's Esther Klein Gallery which had an opening for the Brower Jet Propulsion Laboratory in conjunction with the open house, brought the public into the Science Center to share in the excitement and possibility that is always present.
The 3,600 square foot production space much like the gallery across the street meets a number of needs. It provides access to the materials that will generate both conceptual and physical innovation, so that the life cycle of information and commerce may perpetuate.
Workforce Development Program will provide internship opportunities for Massachusetts students and recent graduates in summer 2010
For Immediate Release: Date: January 12, 2010
Contact: Angus G. McQuilken, Life Sciences Center VP for Communications
Phone: (617) 921-7749 Email: amcquilken@masslifesciences.com
Waltham, MA – The Massachusetts Life Sciences Center today announced the launch of the Center’s Internship Challenge Program for the summer of 2010, the second year of a workforce development program focused on enhancing the talent pipeline for Massachusetts life sciences companies. The program will provide paid internship opportunities at life sciences companies for up to 150 students and recent college graduates who are considering career opportunities in the life sciences.
Ben Franklin TechVentures is raising young, early stage companies and developing businesses in a community charged with entrepreneurship and the spirit of economic development. The incubator/ post incubator facility has the hard to come by wet lab space young biotechs need to develop fully in a region centrally located within reach of New York, Philadelphia and New Jersey. In addition to BFTP of Northeastern Pennsylvania, TechVentures is located within Lehigh University’s Mountain Top Campus alongside local incentives and support; and with an expansion in the works, this is an attractive location for any young start up.
The Nidus Center for Scientific Enterprise focuses on incubating plant biotechnology and life science businesses in St. Louis, Missouri. Until this summer the Nidus Center had occupied 40,000 square feet on the campus of Monsanto Company’s world headquarters. Recently, the Nidus Center moved to the Danforth Plant Science Center campus's Bio-Research and Development growth Park (BRDG-Park) freeing the previously held offices and lab space for Monsanto to operate.
CHAMPAIGN, Illinois (Oct. 22, 2009)—Abbott, the global health care company devoted to discovering new medicines, new technologies, and new ways to manage health, today celebrated the dedication of its new research facility at the Research Park on the University of Illinois campus.
For Immediate Release: Date: 10/28/09
Grant Brings Total MLSC Funding for project to $12.9 Million
 |
|
The Future of Biotech Innovation
|
qed@qb3 - UCSF
Thursday, October 1, 2009
12:00 to 1:00 pm
Byers Hall Room 212
|
|
The biopharmaceutical industry is in turmoil caused by patent cliffs, increasing regulatory and pricing risks, and the poor return on research investments. For decades, biotech startups have been the salvation; companies like Genentech have provided the necessary innovation. But many of the strategies used to build important companies in the 90's are no longer relevant. The need for new therapeutics and positive returns for investors has never been higher. Meeting this need is the challenge that Karl Handelsman (a venture capitalist with CMEA) is taking on. Karl has led the way on spinning out exciting new drug discovery platform companies, including Tetraphase and Intellikine. Join us for a dialogue on what it takes to succeed in today's environment.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaid=189194
|
 Karl Handelsman, Managing Director, CMEA Capital
Karl Handelsman joined CMEA Capital in 1999 and has been involved with numerous CMEA investments such as: Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport. Prior to joining CMEA, Karl was one of the first employees of Tularik, Inc., a drug discovery company, where his business development role spanned corporate partnering, technology licensing, and operations. Karl was also one of the first employees of Whitehead Institute, a premier research organization within Massachusetts Institute of Technology (MIT); and he worked in business development at Millennium Pharmaceuticals. Karl holds graduate degrees from both MIT and Harvard Medical School.
|
| This email was sent to morgan@luminogenics.com by douglas.crawford@ucsf.edu |
| QB3 | 1700 4th Street | Suite 214 | San Francisco | CA | 94158 |
